H2AC20
gene geneOn this page
Also known as H2A/q
Summary
H2AC20 (H2A clustered histone 20, HGNC:4738) is a protein-coding gene on chromosome 1q21.2, encoding Histone H2A type 2-C (Q16777). Core component of nucleosome. It is a common-essential gene (DepMap: required in 93.7% of cancer cell lines).
Histones are basic nuclear proteins that are responsible for the nucleosome structure of the chromosomal fiber in eukaryotes. Two molecules of each of the four core histones (H2A, H2B, H3, and H4) form an octamer, around which approximately 146 bp of DNA is wrapped in repeating units, called nucleosomes. The linker histone, H1, interacts with linker DNA between nucleosomes and functions in the compaction of chromatin into higher order structures. This gene is intronless and encodes a replication-dependent histone that is a member of the histone H2A family.
Source: NCBI Gene 8338 — RefSeq curated summary.
At a glance
- Clinical variants (ClinVar): 6 total
- Cancer dependency (DepMap): dependent in 93.7% of screened cell lines (common-essential)
- MANE Select transcript:
NM_003517
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:4738 |
| Approved symbol | H2AC20 |
| Name | H2A clustered histone 20 |
| Location | 1q21.2 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | H2A/q |
| Ensembl gene | ENSG00000184260 |
| Ensembl biotype | protein_coding |
| OMIM | 602797 |
| Entrez | 8338 |
Gene structure
Transcript identifiers
Ensembl transcripts: 1 — 1 protein_coding
ENST00000331380
RefSeq mRNA: 1 — MANE Select: NM_003517
NM_003517
CCDS: CCDS937
Canonical transcript exons
ENST00000331380 — 1 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001316918 | 149886918 | 149887411 |
Expression profiles
Bgee: expression breadth ubiquitous, 133 present calls, max score 99.62.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 1222.4654 / max 35759.3114, expressed in 1825 samples.
FANTOM5 promoters (2 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 5035 | 1222.1357 | 1825 |
| 201718 | 0.3297 | 172 |
Top tissues by expression
134 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| calcaneal tendon | UBERON:0003701 | 99.62 | gold quality |
| bone marrow cell | CL:0002092 | 99.21 | gold quality |
| colonic epithelium | UBERON:0000397 | 97.04 | gold quality |
| corpus callosum | UBERON:0002336 | 96.80 | gold quality |
| sural nerve | UBERON:0015488 | 95.49 | gold quality |
| adrenal tissue | UBERON:0018303 | 94.57 | gold quality |
| bone marrow | UBERON:0002371 | 91.67 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 86.65 | silver quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 85.69 | gold quality |
| blood | UBERON:0000178 | 83.04 | gold quality |
| tonsil | UBERON:0002372 | 80.37 | gold quality |
| uterine cervix | UBERON:0000002 | 75.66 | gold quality |
| granulocyte | CL:0000094 | 75.45 | gold quality |
| monocyte | CL:0000576 | 75.10 | gold quality |
| leukocyte | CL:0000738 | 74.64 | gold quality |
| mucosa of transverse colon | UBERON:0004991 | 72.70 | gold quality |
| ectocervix | UBERON:0012249 | 72.35 | gold quality |
| adrenal gland | UBERON:0002369 | 71.65 | gold quality |
| hindlimb stylopod muscle | UBERON:0004252 | 71.10 | gold quality |
| right adrenal gland | UBERON:0001233 | 70.49 | gold quality |
| left adrenal gland cortex | UBERON:0035825 | 70.22 | gold quality |
| left ovary | UBERON:0002119 | 70.01 | gold quality |
| mucosa of stomach | UBERON:0001199 | 69.95 | gold quality |
| right lung | UBERON:0002167 | 69.75 | gold quality |
| lower esophagus mucosa | UBERON:0035834 | 69.74 | gold quality |
| left adrenal gland | UBERON:0001234 | 69.62 | gold quality |
| ovary | UBERON:0000992 | 69.56 | gold quality |
| right adrenal gland cortex | UBERON:0035827 | 69.56 | gold quality |
| liver | UBERON:0002107 | 69.16 | gold quality |
| thoracic mammary gland | UBERON:0005200 | 69.14 | gold quality |
Single-cell (SCXA)
Detected in 5 experiment(s), a significant marker in 2.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-MTAB-7052 | yes | 68.18 |
| E-MTAB-9467 | yes | 32.16 |
| E-MTAB-9689 | no | 123.81 |
| E-MTAB-6911 | no | 70.84 |
| E-ANND-3 | no | 2.64 |
Regulation
Is transcription factor: no
Functional genomics
DepMap (CRISPR cell-line fitness): dependent in 93.7% of screened cell lines, common-essential.
Literature-anchored findings (GeneRIF, showing 14)
- deiminated residues were present in H2A (1-56) and H4 (1-52) (PMID:15823041)
- Monoubiquitinated histone H2A in native chromatin coimmunoprecipitates with the endogenous DDB1-CUL4A(DDB2) complex in response to UV irradiation. (PMID:16473935)
- The 2 MDa GCN5 HAT-containing metazoan TFTC/STAGA complexes contain a histone H2A and H2B deubiquitinase activity. (PMID:18206972)
- DDB1-CUL4B(DDB2) is more efficient than DDB1-CUL4A(DDB2) in monoubiquitinating histone H2A in vitro. (PMID:18593899)
- The change in nucleosome core particle conformation induced by global histone acetylation is dependent on H2A/H2A.Z acetylation. (PMID:19385636)
- Study demonstrated that RNF168 is endowed with ubiquitin ligase activity both in vitro and in vivo, which targets histones H2A and H2AX, but not H2B, forming K63 polyubiquitin chains. (PMID:19500350)
- Results demonstrate the potential of C-terminal truncated H2A to contribute to the process of carcinogenesis through epigenetic mechanisms. (PMID:19667409)
- AT1R modify the composition of histone H2A and post-translational modifications. (PMID:20838438)
- L3MBTL2-specific RNAi resulted in increased expression of target genes that exhibited a significant reduction in H2A lysine 119 monoubiquitination. (PMID:21596310)
- Aurora-B-dependent phosphorylation of condensin promotes its association with histone H2A and H2A.Z, which we identify as conserved chromatin ‘receptors’ of condensin (PMID:21633354)
- Our results provide mechanistic insight into how post-translational modification of H2A at the site of a photolesion initiates the repair process and directly affects the stability of the human genome. (PMID:22334663)
- Glycated-H2A histone is better bound by serum anti-DNA autoantibodies in systemic lupus erythematosus patients, and could be a likely trigger for the disease. (PMID:25065453)
- we found an excess of mutations in genes encoding histone H2A and H2B, as well as significant amplification of the segment of chromosome 6p harboring the histone gene cluster containing these genes.We also found frequent deletions of the genes TP53 and MBD3 (a member with CHD4 of the nucleosome remodeling deacetylase complex). (PMID:27791010)
- HIV-Infected Patients: Cross Site-Specific Hydrolysis of H2a and H2b Histones and Myelin Basic Protein with Antibodies against These Three Proteins. (PMID:33143355)
Cross-species orthologs
4 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| ENSDARG00000098739 | ||
| mus_musculus | H2ac20 | ENSMUSG00000068855 |
| rattus_norvegicus | ENSRNOG00000085068 | |
| caenorhabditis_elegans | WBGENE00014240 |
Paralogs (27): MACROH2A2 (ENSG00000099284), H2AZ2 (ENSG00000105968), MACROH2A1 (ENSG00000113648), H2AZ1 (ENSG00000164032), H2AC1 (ENSG00000164508), H2AC6 (ENSG00000180573), H2AC25 (ENSG00000181218), H2AC21 (ENSG00000184270), H2AX (ENSG00000188486), H2AC13 (ENSG00000196747), H2AC11 (ENSG00000196787), H2AC7 (ENSG00000196866), H2AL3 (ENSG00000229674), H2AJ (ENSG00000246705), H2AL1Q (ENSG00000249467), H2AB1 (ENSG00000274183), H2AC12 (ENSG00000274997), H2AC15 (ENSG00000275221), H2AC14 (ENSG00000276368), H2AC16 (ENSG00000276903), H2AC8 (ENSG00000277075), H2AB3 (ENSG00000277745), H2AB2 (ENSG00000277858), H2AC4 (ENSG00000278463), H2AC17 (ENSG00000278677), H2AC18 (ENSG00000288825), H2AC19 (ENSG00000288859)
Protein
Protein identifiers
Histone H2A type 2-C — Q16777 (reviewed: Q16777)
Alternative names: H2A-clustered histone 20, Histone H2A-GL101, Histone H2A/q
All UniProt accessions (1): Q16777
UniProt curated annotations — full annotation on UniProt →
Function. Core component of nucleosome. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. DNA accessibility is regulated via a complex set of post-translational modifications of histones, also called histone code, and nucleosome remodeling.
Subunit / interactions. The nucleosome is a histone octamer containing two molecules each of H2A, H2B, H3 and H4 assembled in one H3-H4 heterotetramer and two H2A-H2B heterodimers. The octamer wraps approximately 147 bp of DNA.
Subcellular location. Nucleus. Chromosome.
Post-translational modifications. Deiminated on Arg-4 in granulocytes upon calcium entry. Monoubiquitination of Lys-120 (H2AK119Ub) by RING1, TRIM37 and RNF2/RING2 complex gives a specific tag for epigenetic transcriptional repression and participates in X chromosome inactivation of female mammals. It is involved in the initiation of both imprinted and random X inactivation. Ubiquitinated H2A is enriched in inactive X chromosome chromatin. Ubiquitination of H2A functions downstream of methylation of ‘Lys-27’ of histone H3 (H3K27me). H2AK119Ub by RNF2/RING2 can also be induced by ultraviolet and may be involved in DNA repair. Monoubiquitination of Lys-120 (H2AK119Ub) by TRIM37 may promote transformation of cells in a number of breast cancers. Following DNA double-strand breaks (DSBs), it is ubiquitinated through ‘Lys-63’ linkage of ubiquitin moieties by the E2 ligase UBE2N and the E3 ligases RNF8 and RNF168, leading to the recruitment of repair proteins to sites of DNA damage. Ubiquitination at Lys-14 and Lys-16 (H2AK13Ub and H2AK15Ub, respectively) in response to DNA damage is initiated by RNF168 that mediates monoubiquitination at these 2 sites, and ‘Lys-63’-linked ubiquitin are then conjugated to monoubiquitin; RNF8 is able to extend ‘Lys-63’-linked ubiquitin chains in vitro. Deubiquitinated by USP51 at Lys-14 and Lys-16 (H2AK13Ub and H2AK15Ub, respectively) after damaged DNA is repaired. H2AK119Ub and ionizing radiation-induced ‘Lys-63’-linked ubiquitination (H2AK13Ub and H2AK15Ub) are distinct events. Phosphorylation on Ser-2 (H2AS1ph) is enhanced during mitosis. Phosphorylation on Ser-2 by RPS6KA5/MSK1 directly represses transcription. Acetylation of H3 inhibits Ser-2 phosphorylation by RPS6KA5/MSK1. Phosphorylation at Thr-121 (H2AT120ph) by DCAF1 is present in the regulatory region of many tumor suppresor genes and down-regulates their transcription. Symmetric dimethylation on Arg-4 by the PRDM1/PRMT5 complex may play a crucial role in the germ-cell lineage. Glutamine methylation at Gln-105 (H2AQ104me) by FBL is specifically dedicated to polymerase I. It is present at 35S ribosomal DNA locus and impairs binding of the FACT complex. Crotonylation (Kcr) is specifically present in male germ cells and marks testis-specific genes in post-meiotic cells, including X-linked genes that escape sex chromosome inactivation in haploid cells. Crotonylation marks active promoters and enhancers and confers resistance to transcriptional repressors. It is also associated with post-meiotically activated genes on autosomes. Lactylated in macrophages by EP300/P300 by using lactoyl-CoA directly derived from endogenous or exogenous lactate, leading to stimulates gene transcription.
Similarity. Belongs to the histone H2A family.
RefSeq proteins (1): NP_003508* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR002119 | Histone_H2A | Family |
| IPR007125 | H2A/H2B/H3 | Domain |
| IPR009072 | Histone-fold | Homologous_superfamily |
| IPR032454 | Histone_H2A_C | Domain |
| IPR032458 | Histone_H2A_CS | Conserved_site |
Pfam: PF00125, PF16211
UniProt features (55 total): modified residue 36, helix 5, cross-link 3, strand 3, turn 3, initiator methionine 1, chain 1, region of interest 1, compositionally biased region 1, mutagenesis site 1
Structure
Experimental structures (PDB)
12 structures.
| PDB | Method | Resolution (Å) |
|---|---|---|
| 7U0G | ELECTRON MICROSCOPY | 2.6 |
| 7U0I | ELECTRON MICROSCOPY | 2.6 |
| 8SYP | ELECTRON MICROSCOPY | 2.6 |
| 8EVI | ELECTRON MICROSCOPY | 2.64 |
| 7U0J | ELECTRON MICROSCOPY | 2.7 |
| 8DK5 | ELECTRON MICROSCOPY | 2.71 |
| 8EVG | ELECTRON MICROSCOPY | 2.75 |
| 8SPU | ELECTRON MICROSCOPY | 2.8 |
| 8EVH | ELECTRON MICROSCOPY | 2.85 |
| 8SPS | ELECTRON MICROSCOPY | 3 |
| 6Y5E | ELECTRON MICROSCOPY | 3.15 |
| 8EVJ | ELECTRON MICROSCOPY | 4.1 |
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q16777-F1 | 91.30 | 0.80 |
Antibody-complex structures (SAbDab): 11 — 7U0G, 7U0I, 7U0J, 8DK5, 8EVG, 8EVH, 8EVI, 8EVJ, 8SPS, 8SPU, 8SYP
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (39): 10, 10, 10, 10, 10, 14, 14, 16, 37, 37, 37, 37, 75, 76, 96, 96, 96, 96, 96, 100 …
Mutagenesis-validated functional residues (1):
| Position | Phenotype |
|---|---|
| 2 | blocks the inhibition of transcription by rps6ka5/msk1. |
Function
Pathways and Gene Ontology
Reactome pathways
55 pathways
| ID | Pathway |
|---|---|
| R-HSA-110328 | Recognition and association of DNA glycosylase with site containing an affected pyrimidine |
| R-HSA-110329 | Cleavage of the damaged pyrimidine |
| R-HSA-110330 | Recognition and association of DNA glycosylase with site containing an affected purine |
| R-HSA-110331 | Cleavage of the damaged purine |
| R-HSA-1221632 | Meiotic synapsis |
| R-HSA-171306 | Packaging Of Telomere Ends |
| R-HSA-1912408 | Pre-NOTCH Transcription and Translation |
| R-HSA-201722 | Formation of the beta-catenin:TCF transactivating complex |
| R-HSA-212300 | PRC2 methylates histones and DNA |
| R-HSA-2299718 | Condensation of Prophase Chromosomes |
| R-HSA-2559580 | Oxidative Stress Induced Senescence |
| R-HSA-2559582 | Senescence-Associated Secretory Phenotype (SASP) |
| R-HSA-2559586 | DNA Damage/Telomere Stress Induced Senescence |
| R-HSA-3214815 | HDACs deacetylate histones |
| R-HSA-3214847 | HATs acetylate histones |
| R-HSA-3214858 | RMTs methylate histone arginines |
| R-HSA-427359 | SIRT1 negatively regulates rRNA expression |
| R-HSA-427389 | ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression |
| R-HSA-427413 | NoRC negatively regulates rRNA expression |
| R-HSA-5250924 | B-WICH complex positively regulates rRNA expression |
| R-HSA-5334118 | DNA methylation |
| R-HSA-5578749 | Transcriptional regulation by small RNAs |
| R-HSA-5617472 | Activation of anterior HOX genes in hindbrain development during early embryogenesis |
| R-HSA-5625886 | Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 |
| R-HSA-5689603 | UCH proteinases |
| R-HSA-5689880 | Ub-specific processing proteases |
| R-HSA-5689901 | Metalloprotease DUBs |
| R-HSA-606279 | Deposition of new CENPA-containing nucleosomes at the centromere |
| R-HSA-68616 | Assembly of the ORC complex at the origin of replication |
| R-HSA-73728 | RNA Polymerase I Promoter Opening |
MSigDB gene sets: 189 (showing top):
REACTOME_MEIOTIC_RECOMBINATION, REACTOME_DNA_REPLICATION, REACTOME_SIGNALING_BY_NOTCH, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, REACTOME_MEIOTIC_SYNAPSIS, FISCHER_G1_S_CELL_CYCLE, GGGTGGRR_PAX4_03, REACTOME_ADHERENS_JUNCTIONS_INTERACTIONS, GOBP_NEGATIVE_REGULATION_OF_GENE_EXPRESSION_EPIGENETIC, DEBIASI_APOPTOSIS_BY_REOVIRUS_INFECTION_UP, CREB_Q3, FISCHER_DREAM_TARGETS, NOUZOVA_TRETINOIN_AND_H4_ACETYLATION, REACTOME_DNA_REPAIR, OCT1_B
GO Biological Process (1): heterochromatin formation (GO:0031507)
GO Molecular Function (3): DNA binding (GO:0003677), structural constituent of chromatin (GO:0030527), protein heterodimerization activity (GO:0046982)
GO Cellular Component (4): nucleosome (GO:0000786), nucleus (GO:0005634), extracellular exosome (GO:0070062), chromosome (GO:0005694)
Reactome top-level categories
Rollup of top-12 pathways:
| Category | Pathways |
|---|---|
| Cellular Senescence | 3 |
| Chromatin modifying enzymes | 3 |
| Depyrimidination | 2 |
| Depurination | 2 |
| Negative epigenetic regulation of rRNA expression | 2 |
| Positive epigenetic regulation of rRNA expression | 2 |
| Meiosis | 1 |
| Telomere Maintenance | 1 |
| Pre-NOTCH Expression and Processing | 1 |
| TCF dependent signaling in response to WNT | 1 |
| Epigenetic regulation of gene expression | 1 |
| Mitotic Prophase | 1 |
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| chromatin | 2 |
| cellular component assembly | 1 |
| heterochromatin boundary formation | 1 |
| negative regulation of gene expression, epigenetic | 1 |
| heterochromatin organization | 1 |
| nucleic acid binding | 1 |
| structural molecule activity | 1 |
| protein dimerization activity | 1 |
| protein-DNA complex | 1 |
| intracellular membrane-bounded organelle | 1 |
| extracellular vesicle | 1 |
| intracellular membraneless organelle | 1 |
Protein interactions and networks
STRING
3578 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| H2AC20 | H4C16 | P02304 | 999 |
| H2AC20 | H3C1 | P02295 | 999 |
| H2AC20 | H2BC21 | Q16778 | 999 |
| H2AC20 | H4C7 | Q99525 | 999 |
| H2AC20 | H3-3A | P06351 | 998 |
| H2AC20 | H3-4 | Q16695 | 998 |
| H2AC20 | H3-7 | Q5TEC6 | 998 |
| H2AC20 | H3-5 | Q6NXT2 | 998 |
| H2AC20 | H3C14 | Q71DI3 | 998 |
| H2AC20 | H1-0 | P07305 | 995 |
| H2AC20 | H1-1 | Q02539 | 994 |
| H2AC20 | TP53BP1 | Q12888 | 991 |
| H2AC20 | H1-5 | P16401 | 989 |
| H2AC20 | RCC1 | P18754 | 968 |
| H2AC20 | CENPA | P49450 | 956 |
IntAct
143 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| CHUK | IKBKB | psi-mi:“MI:0914”(association) | 0.960 |
| VSX1 | USP12 | psi-mi:“MI:0914”(association) | 0.730 |
| OPG044 | DDX3X | psi-mi:“MI:0914”(association) | 0.730 |
| ALDH3A1 | RCCD1 | psi-mi:“MI:0914”(association) | 0.640 |
| CAPZA2 | CNOT1 | psi-mi:“MI:0914”(association) | 0.640 |
| LIN28A | IGF2BP3 | psi-mi:“MI:0914”(association) | 0.640 |
| THOC1 | DDX39A | psi-mi:“MI:0914”(association) | 0.640 |
| LACC1 | DUSP14 | psi-mi:“MI:0914”(association) | 0.530 |
| ULK3 | AIP | psi-mi:“MI:0914”(association) | 0.530 |
| H2AC20 | PPM1G | psi-mi:“MI:0914”(association) | 0.530 |
| RPS2 | MPHOSPH10 | psi-mi:“MI:0914”(association) | 0.530 |
| H2BC26 | PPM1G | psi-mi:“MI:0914”(association) | 0.530 |
| BLOC1S5 | SNAPIN | psi-mi:“MI:0914”(association) | 0.530 |
| P/V/C | KPNA3 | psi-mi:“MI:0914”(association) | 0.530 |
| TOMM20 | TPP1 | psi-mi:“MI:0914”(association) | 0.480 |
| PPM1G | H2BC12 | psi-mi:“MI:0914”(association) | 0.420 |
| H2AC20 | H1-1 | psi-mi:“MI:0915”(physical association) | 0.400 |
| H2AC20 | H2BC9 | psi-mi:“MI:0915”(physical association) | 0.400 |
| H2AC20 | H3-4 | psi-mi:“MI:0915”(physical association) | 0.400 |
| H3C13 | H2AC20 | psi-mi:“MI:0915”(physical association) | 0.400 |
| RAB37 | H2AC20 | psi-mi:“MI:0915”(physical association) | 0.400 |
| Itsn2 | EIF3F | psi-mi:“MI:0914”(association) | 0.350 |
| Mta2 | MTA3 | psi-mi:“MI:0914”(association) | 0.350 |
| MAPK8 | psi-mi:“MI:0914”(association) | 0.350 | |
| NEK4 | E2F8 | psi-mi:“MI:0914”(association) | 0.350 |
| Prdm16 | ESYT2 | psi-mi:“MI:0914”(association) | 0.350 |
| Mecom | ESYT2 | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (499): HIST2H2AC (Biochemical Activity), HIST2H2AC (Reconstituted Complex), HIST2H2AC (Biochemical Activity), HIST2H2AC (Biochemical Activity), HIST2H2AC (Affinity Capture-Western), HIST2H2AC (Affinity Capture-Western), HIST2H2AC (Biochemical Activity), HIST2H2AC (Biochemical Activity), HIST2H2AC (Biochemical Activity), HIST2H2AC (Biochemical Activity), HIST2H2AC (Reconstituted Complex), HIST2H2AC (Affinity Capture-MS), HIST2H2AC (Affinity Capture-MS), HIST2H2AC (Biochemical Activity), HIST2H2AC (Reconstituted Complex)
ESM2 similar proteins: A1A4R1, A9UMV8, C0HKE1, C0HKE2, C0HKE3, C0HKE4, C0HKE5, C0HKE6, C0HKE7, C0HKE8, C0HKE9, P02262, P02263, P02270, P04908, P06897, P0C0S8, P0C0S9, P0C169, P0C170, P0CC09, P13912, P19178, P20671, P21896, P27325, P35061, P35062, P70082, P84052, Q07135, Q16777, Q3ZBX9, Q4FZT6, Q4R3X5, Q64522, Q64523, Q64598, Q6FI13, Q6GSS7
Diamond homologs: A0A097I1R9, A0A097I2B5, A0A0D2UG83, A1A4R1, A1CJ10, A1D8G8, A3LXE7, A3LZZ0, A5DBG4, A5DJJ2, A5DWF1, A5DXC6, A9UMV8, C0HKE1, C0HKE2, C0HKE3, C0HKE4, C0HKE5, C0HKE6, C0HKE7, C0HKE8, C0HKE9, L7HZV6, O74268, P02262, P02263, P02264, P04908, P04909, P04910, P04911, P04912, P06897, P07793, P08844, P0C0S8, P0C0S9, P0C169, P0C170, P0C952
SIGNOR signaling
2 interactions.
| A | Effect | B | Mechanism |
|---|---|---|---|
| SLBP | “up-regulates quantity by expression” | H2AC20 | “translation regulation” |
| DZIP3 | “up-regulates activity” | H2AC20 | monoubiquitination |
Enriched among interaction partners
Reactome pathways and GO biological processes over-represented among this gene’s 191 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.
Reactome pathways:
| Pathway | Partners | Fold | FDR |
|---|---|---|---|
| Packaging Of Telomere Ends | 7 | 12.3× | 2e-04 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | 8 | 11.8× | 8e-05 |
| Cleavage of the damaged pyrimidine | 8 | 11.8× | 8e-05 |
| Recognition and association of DNA glycosylase with site containing an affected purine | 7 | 11.4× | 2e-04 |
| Cleavage of the damaged purine | 7 | 11.4× | 2e-04 |
| SIRT1 negatively regulates rRNA expression | 8 | 10.9× | 1e-04 |
| DNA Damage/Telomere Stress Induced Senescence | 8 | 10.4× | 1e-04 |
| Meiotic synapsis | 9 | 10.2× | 8e-05 |
GO biological processes:
| GO term | Partners | Fold | FDR |
|---|---|---|---|
| positive regulation of macroautophagy | 5 | 16.1× | 5e-03 |
| energy homeostasis | 6 | 9.9× | 7e-03 |
| heterochromatin formation | 6 | 9.3× | 8e-03 |
| nucleosome assembly | 8 | 6.8× | 7e-03 |
| protein phosphorylation | 15 | 6.2× | 2e-05 |
| chromatin organization | 10 | 6.0× | 4e-03 |
Disease & clinical
Clinical variants and AI predictions
ClinVar
6 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 6 |
| Likely benign | 0 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
67 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 1:149887062:C:T | donor_gain | 0.8700 |
| 1:149887088:C:T | donor_gain | 0.8700 |
| 1:149887087:GCAAC:G | donor_gain | 0.8300 |
| 1:149887138:TCCTC:T | donor_gain | 0.7700 |
| 1:149887001:C:T | donor_gain | 0.7300 |
| 1:149887199:G:GT | donor_gain | 0.7300 |
| 1:149886997:G:GT | donor_gain | 0.6800 |
| 1:149887091:C:G | donor_gain | 0.5600 |
| 1:149887051:TCCCG:T | donor_loss | 0.5100 |
| 1:149887052:CCCGG:C | donor_loss | 0.5100 |
| 1:149887053:CCG:C | donor_loss | 0.5100 |
| 1:149887054:CG:C | donor_loss | 0.5100 |
| 1:149887055:GGTAG:G | donor_loss | 0.5100 |
| 1:149887056:GTAGG:G | donor_loss | 0.5100 |
| 1:149887057:T:A | donor_loss | 0.5100 |
| 1:149887058:A:C | donor_loss | 0.5000 |
| 1:149887059:G:GC | donor_loss | 0.4700 |
| 1:149887252:A:T | donor_gain | 0.4500 |
| 1:149887060:G:C | donor_loss | 0.4000 |
| 1:149887056:G:GG | donor_gain | 0.3800 |
| 1:149887251:G:GT | donor_gain | 0.3700 |
| 1:149887050:TTCCC:T | donor_loss | 0.3600 |
| 1:149887054:C:A | donor_gain | 0.3500 |
| 1:149887059:G:A | donor_gain | 0.3500 |
| 1:149887102:G:A | donor_gain | 0.3500 |
| 1:149887229:GCT:G | acceptor_gain | 0.3400 |
| 1:149887061:G:T | donor_gain | 0.3300 |
| 1:149887228:A:AG | acceptor_gain | 0.3200 |
| 1:149887229:G:GG | acceptor_gain | 0.3200 |
| 1:149887107:G:A | donor_gain | 0.3100 |
AlphaMissense
814 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 1:149887045:T:A | L24H | 1.000 |
| 1:149887123:T:A | V50D | 1.000 |
| 1:149887135:C:A | A54E | 1.000 |
| 1:149887146:T:C | Y58H | 1.000 |
| 1:149887150:T:C | L59P | 1.000 |
| 1:149887155:G:C | A61P | 1.000 |
| 1:149887156:C:A | A61D | 1.000 |
| 1:149887159:A:T | E62V | 1.000 |
| 1:149887165:T:C | L64P | 1.000 |
| 1:149887167:G:A | E65K | 1.000 |
| 1:149887171:T:C | L66P | 1.000 |
| 1:149887174:C:A | A67E | 1.000 |
| 1:149887176:G:C | G68R | 1.000 |
| 1:149887176:G:T | G68C | 1.000 |
| 1:149887177:G:A | G68D | 1.000 |
| 1:149887177:G:T | G68V | 1.000 |
| 1:149887185:G:C | A71P | 1.000 |
| 1:149887186:C:A | A71D | 1.000 |
| 1:149887191:G:C | D73H | 1.000 |
| 1:149887192:A:T | D73V | 1.000 |
| 1:149887210:T:A | I79N | 1.000 |
| 1:149887218:C:A | R82S | 1.000 |
| 1:149887231:T:C | L86P | 1.000 |
| 1:149887234:C:A | A87D | 1.000 |
| 1:149887240:G:C | R89P | 1.000 |
| 1:149887245:G:C | D91H | 1.000 |
| 1:149887246:A:C | D91A | 1.000 |
| 1:149887246:A:G | D91G | 1.000 |
| 1:149887246:A:T | D91V | 1.000 |
| 1:149887255:T:C | L94P | 1.000 |
dbSNP variants (sampled 300 via entrez): RS1002085119 (1:149885572 G>A), RS1004208294 (1:149886803 C>T), RS1005621517 (1:149885489 G>C), RS1008980388 (1:149887855 C>T), RS1014554334 (1:149887856 G>A), RS1015832667 (1:149886687 G>A,C), RS1016899751 (1:149885510 G>C), RS1020749141 (1:149886077 T>A,C), RS1020781430 (1:149885606 G>A), RS1025322852 (1:149885130 T>C), RS1025523015 (1:149887031 G>A,C), RS1028575428 (1:149887381 C>T), RS1028635793 (1:149887522 A>C,G), RS1029622454 (1:149886527 G>A), RS1033866495 (1:149886839 A>C,G)
Disease associations
OMIM: gene MIM:602797 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
0 associations (top):
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
49 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Benzo(a)pyrene | decreases expression, increases expression | 4 |
| bisphenol F | increases expression, affects cotreatment | 2 |
| bisphenol A | decreases expression, affects cotreatment, increases expression | 2 |
| sodium arsenite | decreases expression, increases expression | 2 |
| Acetaminophen | increases expression | 2 |
| Valproic Acid | decreases expression, decreases methylation | 2 |
| Aflatoxin B1 | decreases expression, decreases methylation | 2 |
| Copper Sulfate | increases expression, decreases expression | 2 |
| afuresertib | decreases expression | 1 |
| TAK-243 | decreases sumoylation | 1 |
| propionaldehyde | decreases expression | 1 |
| 2-methyl-4-isothiazolin-3-one | decreases expression | 1 |
| arsenite | affects binding, increases reaction | 1 |
| tris(1,3-dichloro-2-propyl)phosphate | decreases expression | 1 |
| ferrous chloride | increases expression | 1 |
| hydroquinone | decreases expression | 1 |
| chloropicrin | decreases expression | 1 |
| nickel acetate | decreases ubiquitination, increases ubiquitination | 1 |
| nutlin 3 | affects cotreatment, increases secretion | 1 |
| bisphenol B | increases expression | 1 |
| abrine | increases expression | 1 |
| (4-amino-1,4-dihydro-3-(2-pyridyl)-5-thioxo-1,2,4-triazole)copper(II) | increases expression | 1 |
| jinfukang | affects cotreatment, decreases expression | 1 |
| (+)-JQ1 compound | decreases expression | 1 |
| bisphenol AF | increases expression | 1 |
| Sunitinib | decreases expression | 1 |
| Zoledronic Acid | increases expression | 1 |
| Arsenic Trioxide | increases expression | 1 |
| Benztropine | increases expression | 1 |
| Cannabidiol | increases expression | 1 |
Cellosaurus cell lines
3 cell lines: 3 embryonic stem cell
First 10 cell lines (id-ordered, not curated):
| Cellosaurus | Name | Category | Sex |
|---|---|---|---|
| CVCL_A2Q8 | SEES3-1V human HIST2H2AC, clone1 | Embryonic stem cell | Male |
| CVCL_A2Q9 | SEES3-1V human HIST2H2AC, clone2 | Embryonic stem cell | Male |
| CVCL_A2R0 | SEES3-1V human HIST2H2AC, clone3 | Embryonic stem cell | Male |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.